Profile

Identity, professional record and current appointments.

Overview

Professional record at a glance

A concise summary of information supported by the cited public sources. Missing information is treated as unknown, not as a negative finding.

Current roles
33 current organizations shown on this profile
Board positions
33 supported by public sources, 0 supplied by the profile owner
Committee roles
4Roles supported by the sources cited on this profile
Qualifications
Not establishedNo qualification is currently confirmed by the cited sources

Professional narrative

About

Alpha has not published a narrative summary because the current public source set is not sufficient.

Current roles

Appointments & responsibilities

Board appointments

Governance

Board appointments, committee responsibilities and disclosed relationships.

Connections

Explore the roles, education and affiliations published in this record.

ACADIA PHARMACEUTICALS INC

Open ACADIA PHARMACEUTICALS INC profile →

Director at ACADIA PHARMACEUTICALS INC

2016-01-01 → End not stated

current · source reported

Observed: 2026-09-12

ACADIA PHARMACEUTI…ACADIA PHARMACEUTICALS INCCYTOKINETICS INCCYTOKINETICS INCMADRIGAL PHARMACEU…MADRIGAL PHARMACEUTICALS, INC.James M. Daly

Dashed lines mark past roles. Select a connection to see its dates and sources.

Relationship map

Connected through the public record

Direct relationships from verified facts and published résumé records. Private connections are excluded.

Direct public links only

Only published affiliations are shown here. Private relationships require authorized access.

Experience

Career history, education, credentials and public contributions.

Published record

Featured coverage

Selected publications and public sources used to establish this profile. Inclusion records provenance; it is not an endorsement.

Source 1 · Sec FilingACADIA PHARMACEUTICALS INC director board sourceSupports Board membership, Committee assignments, Director since, Board independence.Open sourceSource 2 · Sec FilingCYTK DEF 14A director slateSupports Board role, Committee assignments.Open sourceSource 3 · Sec FilingAMRX DEF 14A executive officersSupports AI and ML experience, Cybersecurity experience, Executive company, Executive title, Technology background.Open sourceSource 4 · Sec FilingMDGL DEF 14A director slateSupports AI and ML experience, Board role, Committee assignments, Cybersecurity experience, Technology background.Open source

Basis

Identifiers, sources, dates and record limitations.

Identifiers

Alpha ID
alpha:person:james-m-daly
Record version
public-0

Sources

Sources and published information

Each item links to the public source used to support it. When sources disagree, the item is clearly marked for review.

AI and ML experience · CorroboratedAI and ML experience: not identified in the cited filingSupported by 2 public records2 sources
Verification
Corroborated
Confidence
72%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 14, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Board independence · CorroboratedIndependent directorSupported by 2 public records2 sources
Verification
Corroborated
Confidence
95%
Last reviewed
May 3, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

Board membership · CorroboratedServes on the board of ACADIA PHARMACEUTICALS INCSupported by 3 public records2 sources
Verification
Corroborated
Confidence
95%
Last reviewed
May 3, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

Board membership · CorroboratedServes on the board of Madrigal PharmaceuticalsSupported by 4 public records3 sources
Verification
Corroborated
Confidence
95%
Last reviewed
May 16, 2026
Board role · CorroboratedBoard role: DirectorSupported by 3 public records3 sources
Verification
Corroborated
Confidence
92%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed Apr 24, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 8, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Committee assignments · CorroboratedNo committee assignment disclosed in the cited filingSupported by 2 public records2 sources
Verification
Corroborated
Confidence
95%
Last reviewed
May 3, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

Committee assignments · Source reportedCommittee assignments: Audit, Compensation1 source
Verification
Source reported
Confidence
88%
Last reviewed
Apr 24, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed Apr 24, 2026

Committee assignments · Source reportedCommittee assignments: Audit, Nominating/Governance1 source
Verification
Source reported
Confidence
88%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Committee assignments · Source reportedCommittee assignments: Transactions1 source
Verification
Source reported
Confidence
88%
Last reviewed
May 8, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 8, 2026

Cybersecurity experience · CorroboratedCybersecurity experience: not identified in the cited filingSupported by 2 public records2 sources
Verification
Corroborated
Confidence
72%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 14, 2026

Executive company · Source reportedExecutive at Amneal Pharmaceuticals, Inc.1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 14, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 14, 2026

Executive title · Source reportedExecutive title: Executive Vice President, Chief Legal Officer and Corporate Secretary1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 14, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 14, 2026

Technology background · CorroboratedTechnology background: not identified in the cited filingSupported by 2 public records2 sources
Verification
Corroborated
Confidence
72%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 14, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

View all sources9 records
  1. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

    Supports: Board membership · Committee assignments · Director since · Board independence

  2. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed Apr 24, 2026

    Supports: Board role · Committee assignments

  3. https://www.sec.gov/Archives/edgar/data/1070494/000119312526174163/acad-20260423.htm

    Sec Proxy · Tier not stated · Reviewed Apr 24, 2026

    Supports: Director at ACADIA PHARMACEUTICALS INC (NASDAQ: ACAD)

  4. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 8, 2026

    Supports: Board role · Committee assignments

  5. https://www.sec.gov/Archives/edgar/data/1061983/000114036126015364/ny20063687x771_def14a.htm

    Sec Proxy · Tier not stated · Reviewed May 8, 2026

    Supports: Director at CYTOKINETICS INC (NASDAQ: CYTK)

  6. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 14, 2026

    Supports: AI and ML experience · Cybersecurity experience · Executive company · Executive title · Technology background

  7. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

    Supports: AI and ML experience · Board role · Committee assignments · Cybersecurity experience · Technology background

  8. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

    Supports: Board membership · Committee assignments · Director since · Board independence

  9. https://www.sec.gov/Archives/edgar/data/1157601/000110465925041254/tm2512589-3_def14a.htm

    Sec Proxy · Tier not stated · Reviewed May 1, 2026

    Supports: Director at MADRIGAL PHARMACEUTICALS, INC. (NASDAQ: MDGL) · Board membership